The Lymphoma Channel: Diffuse Large B-Cell Lymphoma

Explore the latest updates and expert interviews

The Lymphoma Channel on VJHemOnc is supported by Janssen Pharmaceuticals (a Johnson & Johnson Company), Takeda, Karyopharm Therapeutics and MorphoSys. The supporters have no influence over the production of the content.

Welcome to The Diffuse Large B-Cell Lymphoma (DLBCL) Channel

VJHemOnc presents the most recent updates in diffuse large B-cell lymphoma (DLBCL) directly from the experts themselves. The DLBCL Channel covers all of the latest developments presented at international congresses in the form of exclusive video interviews, podcasts, and roundtable discussions.

Delve into The DLBCL Channel to hear what world-renowned experts have to say in diagnosing DLBCL, and the future treatment landscape for DLBCL, including exciting trial data on various CAR T-cell therapies and other immunotherapies.

View Aggressive & Diffuse Large B-Cell Lymphoma Overview Page
Novel treatment approaches for early-stage DLBCL 2:03
Novel treatment approaches for early-stage DLBCL
Wendy Osborne • 24 Apr 2023
Risk factors to predict post-CD19 CAR-T cell therapy outcomes in patients with LBCL 4:05
Risk factors to predict post-CD19 CAR-T cell therapy outcomes in patients with LBCL
Roni Shouval • 27 Apr 2023
Selecting between autoSCT & CAR-T in DLBCL: patient selection, drug access, and long-term efficacy 2:25
Selecting between autoSCT & CAR-T in DLBCL: patient selection, drug access, and long-term efficacy
Christian Gisselbrecht • 25 Apr 2023
Psychosocial experiences in patients with DLBCL receiving CAR-T therapy vs other therapies 2:13
Psychosocial experiences in patients with DLBCL receiving CAR-T therapy vs other therapies
Lorna Warwick • 24 Apr 2023
The benefit of CAR-T therapy over autoSCT in 3L DLCBL & the promise of bispecifics in this setting 0:58
The benefit of CAR-T therapy over autoSCT in 3L DLCBL & the promise of bispecifics in this setting
Marjolein van der Poel • 25 Apr 2023
Managing early & late relapse after first-line therapy for DLBCL 1:39
Managing early & late relapse after first-line therapy for DLBCL
Marjolein van der Poel • 25 Apr 2023
Weighing up the pros and cons of CAR-T therapy and bispecfic antibodies in R/R DLBCL 2:37
Weighing up the pros and cons of CAR-T therapy and bispecfic antibodies in R/R DLBCL
Anna Sureda • 4 May 2023
The benefits of CAR-T therapy in 2L over 3L in R/R DLBCL 1:08
The benefits of CAR-T therapy in 2L over 3L in R/R DLBCL
Anna Sureda • 4 May 2023
Current and emerging indications for CAR-T therapy in LBCL 1:41
Current and emerging indications for CAR-T therapy in LBCL
Anna Sureda • 4 May 2023
The impact of tafasitamab on the efficacy and safety of CD19 CAR-T therapy in preclinical models 2:25
The impact of tafasitamab on the efficacy and safety of CD19 CAR-T therapy in preclinical models
Reona Sakemura • 2 May 2023
Economic burden of CAR-T therapy from a UK perspective 1:11
Economic burden of CAR-T therapy from a UK perspective
Andrew Davies • 24 Apr 2023
Updates in the treatment of R/R LBCL: promising novel agents in the pipeline 1:18
Updates in the treatment of R/R LBCL: promising novel agents in the pipeline
Wendy Osborne • 24 Apr 2023
Primary analysis of the Phase III TRANSFORM study: liso-cel in second-line LBCL 2:40
Primary analysis of the Phase III TRANSFORM study: liso-cel in second-line LBCL
Andrew Davies • 24 Apr 2023
REMoDL-B: bortezomib + R-CHOP versus R-CHOP in patients with DLBCL 1:44
REMoDL-B: bortezomib + R-CHOP versus R-CHOP in patients with DLBCL
Andrew Davies • 24 Apr 2023
CARBON: results of Phase I study of CTX110 allogeneic CRISPR-CAS9-engineered CAR-Ts in R/R LBCL 5:32
CARBON: results of Phase I study of CTX110 allogeneic CRISPR-CAS9-engineered CAR-Ts in R/R LBCL
Joseph McGuirk • 24 Apr 2023
Clinical efficacy and safety of CT-P10 in patients with DLBCL 0:44
Clinical efficacy and safety of CT-P10 in patients with DLBCL
Mark Bishton • 24 Apr 2023

The Lymphoma Channel on VJHemOnc is supported by Janssen Pharmaceuticals (a Johnson & Johnson Company), Takeda, Karyopharm Therapeutics and MorphoSys.

The supporters have no influence over the production of the content.

If you are interested in becoming a supporter of The Lymphoma Channel, please contact us.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals